Pomerantz Law Firm Issues Investor Alert on Aquestive Therapeutics Class Action Lawsuit

Pomerantz LLP, a well-known name in the realm of class action litigation, has raised an important alert for investors regarding Aquestive Therapeutics, Inc. (NASDAQ: AQST). A class action lawsuit has been initiated against the company, following concerns of potential securities fraud and illegal business practices. Investors who have suffered losses as a result of their investments in Aquestive Therapeutics are encouraged to contact Pomerantz to explore their legal options.

Details of the Class Action

The current class action lawsuit relates to allegations against Aquestive and its senior officers and directors. These claims center around whether false or misleading statements were made regarding the company’s operations and financial status, specifically concerning their product, Anaphylm (Dibutepinephrine) sublingual film. The lawsuit emphasizes the significance of proper disclosures to investors and the consequences of failing to meet those obligations.

The deadline for investors to join the lawsuit is approaching, with the cut-off date of May 4, 2026, for investors wishing to request the court to designate them as lead plaintiffs. This deadline serves to highlight the urgent need for affected investors to act swiftly. Interested parties can contact Danielle Peyton at Pomerantz LLP for assistance.

Recent Developments

On January 9, 2026, Aquestive received a letter from the U.S. Food and Drug Administration (FDA) citing deficiencies that obstructed further discussions regarding the label of Anaphylm. This letter indicated that the review of the Anaphylm New Drug Application (NDA) would continue indefinitely, raising red flags that significantly impacted the investor community. Following this announcement, the stock price of Aquestive saw a dramatic decline, plummeting by $2.30 per share, which amounted to a 37.04% decrease, closing at $3.91 that same day.

This decline has prompted Pomerantz LLP to act in order to protect the rights of investors who may have beenaffected by these developments. The firm has a robust history of securing substantial recoveries for victims of securities fraud, as recognized by its long-standing legacy in corporate litigation.

Who Should Act?

Investors who acquired Aquestive securities during the class period are strongly urged to take action before the deadline. It is essential for them to be aware of their rights in light of the ongoing legal proceedings. Interested investors should inquire by email, ensuring to provide necessary contact details such as mailing address and phone number, along with the number of shares purchased.

The opportunity to potentially lead the class action serves as a critical message that stakeholders can still pursue their grievances and seek remedies for the losses incurred.

About Pomerantz LLP

Founded by the late Abraham L. Pomerantz, regarded as a pioneer in securities class actions, Pomerantz LLP stands out as one of the premier firms in handling corporate, securities, and antitrust class litigation. Their commitment has persisted for over 85 years, advocating for justice for those wronged by securities fraud or corporate misconduct.

For more detailed information, prospective class members can visit Pomerantz Law and obtain a copy of the complaint. Pomerantz’s dedicated approach to legal representation assures clients that they are in capable hands during these challenging times.

In conclusion, the ongoing case against Aquestive Therapeutics highlights the importance of investor vigilance, the relevance of timely legal action, and the risks associated with corporate disclosures. As this situation evolves, the proactive measures taken by both investors and legal representatives will play a crucial role in determining the outcome of the class action lawsuit.